The methods of the present disclosure are directed toward methods of diagnosis and treatment of cancer in a subject. The present disclosure provides methods of diagnosing abnormal cells in a subject by measuring the level of Hexim-1 in a sample from the subject, where elevated levels of Hexim-1 indicate abnormal cells. This disclosure further provides methods of treating cancer or hyperplasia, comprising administering to a subject in need thereof a therapeutically effective amount of Hexim-1 or an activator of Hexim-1 expression or activity.

The present invention relates to a method for classifying a prostate cancer in a subject, the method comprising the steps of a) determining a gene expression level or gene expression pattern of the genes F3 and IGFBP3 in a sample from the subject and b) classifying the tumor by comparing the gene expression level determined in a) with a reference gene expression of the same genes in reference patients known to have a high risk or low risk tumor respectively. In addition the invention relates to a method for determining prognosis of a subject diagnosed with prostate cancer, a method for making a treatment decision for a subject diagnosed with prostate cancer and a solid support or a kit for classifying a tumor in a subject diagnosed with prostate cancer.

Embodiments of the invention provide high affinity recombinant EpCAM-binding antibodies. Methods of using a such antibodies as imaging agents, diagnostics and therapeutics are also provided. Dual-nuclear and fluorescently labeled or singly fluorescently labeled contrast agents promise the advantage of molecularly-guided surgical resection via surgical field near-infrared fluorescence (NIRF) imaging following (in the case of dual labeled agents) nuclear imaging for general localization. Currently, nodal staging of most cancers is performed following lymph node (LN) biopsy and dissection for subsequent pathological examination.

Active-on-active microelectronic devices are described. For example, a first die is on a second die with a bottom surface of a first substrate facing a top surface of a second substrate, respectively, to provide a die stack. The first and second dies each have metal layers in ILD layers to provide a first stack structure and a second stack structure, respectively. The first stack structure is interconnected to an upper end of a TSV of the first die. A metal layer of the second stack structure near a bottom surface of the first substrate is interconnected to a lower end of the TSV. A power distribution network layer of the second stack structure is located between lower and upper layers of the metal layers thereof. A transistor located at least in part in the second substrate is interconnected to the power distribution network layer to receive supply voltage or ground.

In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2α axis of the UPR adaptive response. Agents that disrupt PERK-eIF2α pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.

Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs.

The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.

The disclosure provides a method of predicting de novo resistance to androgen receptor (AR) targeted therapy in a tumor of a prostate cancer patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characteristization of nucleated cells in a blood sample obtained from the patient to generate circulating tumor cell (CTC) data, wherein the analysis comprises determining a measurable feature of a panel of traditional and non-traditional CTC biomarkers for de novo resistance to androgen receptor (AR) targeted therapy, and (b) evaluating the CTC data to determine the probability of de novo resistance to the AR targeted therapy in the tumor of the prostate cancer patient. Further disclosed are the panel of traditional and non-traditional CTC biomarkers for the methods.

The present invention relates to a method for detecting the presence or absence of a prostate cancer in a subject, the method comprising steps of: providing a semen sample obtained from the subject; and detecting at least one biomarker or determining the concentration of at least one biomarker. The present invention also relates to lysis buffers, monoclonal antibodies, and kits that can be used in such methods.

The present invention relates to a composition comprising at least three primary antibodies or fragments thereof, wherein the at least three antibodies or fragments thereof binds specifically to at least three different proteins, and wherein the at least three different proteins are AMCAR, CK 5/6, and HMWC. Methods for using the composition in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits comprising said composition, and optionally, instructions of its use.